ClinicalTrials.gg
TerminatedNCT00792831Updated Jan 27, 2022

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

A Phase 2 interventional study of ITF2357 in Chronic Lymphocytic Leukemia, sponsored by Italfarmaco. Terminated at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by Italfarmaco · Phase 2, Interventional, and Treatment

Why this study was terminated
Protocol needs complete restructuring in order to make it feasible and to complete the enrollment of 23 patients.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 166 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Italy — 31 open to participants now, 53 under way, 15 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Italy.

Enrollment
139th of 141
3 · median 171
Started
2008
with 3 others
Phase 2
40 of 166
8 open now
Registered
36th of 166
by date

Among the 166 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Italy, this one is the 139th largest by enrollment of the 141 interventional ones that give a count, is one of 4 that started in 2008, is one of 40 in phase 2, and was the 36th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

31 of the 166 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 166 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Italy, or all of them as a file.
02

Study summary

Primary objective:

  • To determine overall response-rate, complete response (CR) or partial response (PR)

Secondary objectives:

  • To assess the safety and tolerability of ITF2357;
  • to assess total rate of responders (complete + partial responders);
  • to determine the 6 months progression free survival;
  • to determine the effects of the drug on haematological parameters.
Read the detailed description

This is an open label, un-controlled, phase II, pilot clinical trial testing ITF2357 in a population of CLL patients relapsed after or refractory to conventional chemotherapy or relapsed after autologous bone marrow transplantation.

Patient received ITF 2357 orally at the dose of 100 mg x 2/die for three months with subsequent dose modifications if requested by the patient's conditions.

The study was prematurely discontinued due to recruitment problems. Since February 2008, date of first patient's first visit, until April 2009, date of early study discontinuation, only 3 patients were enrolled. The Sites involved in the study were 6 but only two actively recruited patients.

CLL is the most frequent type of leukemia in the western world and affects mainly elderly individuals, although about one third of patients are less than 60 years of age at diagnosis.

CLL is a heterogeneous disease characterised by a surprisingly diverse clinical course with patients that may have an overall survival time ranging from months to decades.

CLL accounts for approximately 7000 new cases and 4500 deaths per year in the US.

Chemotherapeutic treatment of CLL is largely ineffective and despite new emerging therapies, CLL still remains an incurable disease.

ITF 2357 is a novel and proprietary molecule synthesized by Italfarmaco S.p.A. Research Laboratories, provided with an established and powerful HDAC-inhibitory activity (see below for further details). It is being developed for a range of possible clinical applications both in oncohaematological conditions and in chronic inflammatory diseases. The former application is consistent with the well known antitumor pharmacological properties of HDAC-inhibitors as a family (i.e. cell-cycle arrest, pro-apoptotic and cell-differentiating effects); the latter application (chronic inflammation) is based of the demonstrated anticytokine effect of ITF 2357.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • CLL
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CLL according to the NCI Working Group criteria.
  • Male and female patients of age >18 and ≤75 years
  • Patients within 1 month after conventional chemotherapy (>1 polychemotherapy regimen) or relapsed within 3 months after bone marrow transplantation
  • performance score of ≤2
  • Lymphocytes ≥10.0x10\^9/L and >75.0x10\^9/L after recovery from a previous therapy
  • Percentage of CD19+/CD5+ leukemic cells >50%
  • Adequate cardiac, pulmonary and renal function, as defined by >45%, FEV >50% and creatinine ≤1.5 or ≥50ml/min
  • Serum \<1.5xULN, and ALT \<2.5xULN
  • Serum potassium, phosphorus, total calcium, magnesium >LLN
  • Normal values for FT4 and TSH (patients may be on thyroid hormone replacement)
  • Negative test for beta-HCG for women in fertile age
  • Documentation of written to participate in the trial
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Patients with haemolytic anaemia, Autoimmune Thrombocytopenic Purpura and Fischer Evans Syndrome.
  • Patients with other autoimmune diseases.
  • Patients with a marked baseline prolongation of (e.g. repeated demonstration of a QTc interval >450 ms).
  • Patients with history of additional risk factors for torsade de pointes (e.g. hearth failure, family history of Long QT Syndrome)
  • The use of concomitant medications with potential risk of torsade de pointes and/or that can prolong QTc interval
  • Prior treatment with an HDAC inhibitor.
  • Treatment with Rituximab or Alemtuzumab within 90 days prior to study therapy.
  • Patients positive, patients with active EBV, , infection or liver cirrhosis
  • Patients with active uncontrolled viral or bacterial or mycotic infection.
  • Major surgeries within 4 weeks from study start or not fully recovered from any previous surgical procedure.
  • Presence of any medical or psychiatric condition which may limit full compliance with the study or increase the risk associated with study participation or study drug administration.
  • Patients in treatment with within 1 month before study start
  • Significant cardiovascular disease (i.e., uncontrolled arrhythmias, unstable angina), or a major thromboembolic event (myocardial infarction, stroke, , pulmonary embolism, or non-catheter-related deep-vein thrombosis) in the last 6 months.
  • Uncontrolled hypertension.
  • Malabsorption syndromes.
  • Breast feeding women
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    ITF2357

    ITF2357 was supplied as hard gelatine capsules for oral administration at the strength of 100 or 50 mg. Patients had to receive ITF2357 100 mg x 2/die at 12-hour intervals, in fed conditions, for three consecutive months.

    Drug: ITF2357

Interventions

  • Histone-Deacetylase Inhibitor

    Also known as: Givinostat

06

What researchers measure

Primary outcomes

  1. Rate of complete response (CR) or partial response (PR) to ITF2357 in all patients

    ITF2357 was given at 100 mg x 2/die for up to three months. A positive response was defined to be a patient experiencing a complete or partial remission. Complete remission (CR) Absence of lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms. Normal blood count: neutrophils ≥1.5x109/L, platelets \>100x109/L, lymphocytes ≤4.0x109/L, Hb \>11.0 g/dL (not supported by transfusion), BM biopsy: normal cellularity, lymphocytosis \<30%. Partial remission (PR) ≥50% reduction in blood lymphocytes and ≥50% reduction in lymphadenophaty and/or 50% reduction in hepatomegaly and/or splenomegaly. Neutrophils ≥1.5x109/L or 50% improvement over baseline, platelets \>100x109/L or 50% improvement over baseline, Hb \>11.0 g/dL or 50% improvement over baseline (not supported by transfusion) It was considered PR * CR with nodular infiltrates at bone marrow biopsy (RPn) * CR with persistent anemia and thrombocytopenia therapy-related

    Time frame: 13 weeks

Secondary outcomes

  1. Total rate of responders (complete+partial responders)

    ITF2357 was given at 100 mg x 2/die for up to three months

    Time frame: 13 weeks

  2. Six months progression free survival.

    ITF2357 was given at 100 mg x 2/die for up to three months

    Time frame: Up to 6 months

  3. Number of subjects experiencing an adverse vents (AE), type, frequency, severity, timing and relatedness of AE

    ITF2357 was given at 100 mg x 2/die for up to three months

    Time frame: Throughout the study till 90 days post treatment

07

Study locations

1 site
  • Department of Internal Medicine and Public Health, University of Perugia
    Perugia, 06074, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2008, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2008
First posted
Nov 18, 2008
Start
Feb 2008
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00792831
Lead sponsor
Italfarmaco
Responsible party
Sponsor
First posted
Nov 18, 2008
Start date
Feb 2008
Primary completion
Apr 2009
Completion
Apr 2009
Last update
Jan 27, 2022

Study contacts

Massimo Martelli, MD
study director · Department of Internal Medicine and Public Health, University of Perugia

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Givinostat

Start the discussion